Preventive Services Applicability, Coverage, Coding, and Reimbursement
Customize your policy alerts
Sign up for all fallon_community_health_plan_inc policy alerts
Know when fallon_community_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Fallon Community Health Plan's coverage, billing, and reimbursement rules for preventive services across specified Fallon Health products, and outlines code- and modifier-specific guidance that affects providers and member cost-sharing.
CMS NCD 210.15 directs Medicare to cover all forms of PrEP (oral and injectable) under Medicare Part B with no deductibles, copayments, or coinsurance for individuals at increased risk of HIV acquisition.
Effective January 1, 2025, physicians and health care practitioners can bill specified codes for PrEP services and drugs (lists provided).
Coverage Criteria and Service-Specific Rules
General applicability and member cost-sharing
Applies to the listed Fallon Health products; preventive services provided by in‑network providers have no member cost-sharing except when a nonpreventive service is billed in conjunction with a preventive service.
Billing and modifier 25 guidance
Billing and reimbursement rules for preventive services, proper diagnosis placement, and use of modifier 25.
Clinical preventive service specifics
Service‑specific coverage aligned with USPSTF recommendations, Medicare NCDs, and MassHealth rules.
MassHealth screening coding and billing rules
MassHealth-specific screening and modifier requirements for pediatric, caregiver, behavioral health, and perinatal screenings.
Birth control coverage and coding
Contraceptive coverage notes and related procedural and supply coding guidance.
Breast Cancer Screening
Breast cancer screening coverage, age‑based frequency, modalities, and prior authorization requirements for high‑tech imaging.
Cervical and Chlamydia/Gonorrhea Screening
Cervical cancer and Chlamydia/Gonorrhea screening follow USPSTF recommendations; frequency and codes defined.
Colorectal Cancer Screening
Colorectal cancer screening modalities, age ranges, frequency limits, and follow‑on colonoscopy rules aligned with USPSTF and Medicare updates.
BRCA Testing
BRCA genetic testing considered preventive in some circumstances and requires prior authorization.
Birth Control Coverage (additional entry)
Birth control services and supplies are covered as preventive with specific procedural and supply codes.
Colorectal screening (duplicate/service detail)
Colorectal screening billing and interrupted procedure guidance.
Annual depression screening
Annual depression screening coverage rules and billing constraints.
Fluoride varnish
Fluoride varnish application and billing instructions for MassHealth and Community Care members.
Hearing screening in children
Pediatric hearing screening guidance and code use.
Hepatitis screening
Hepatitis B and C screening criteria, populations, and coding guidance.
Special Fallon coverage rules
- A single one‑time HCV screening is covered for adults born 1945–1965 (bill with Z11.59).
- Repeat annual screening is covered only for persons with continued illicit injection drug use (bill with Z72.89 and/or F19.20).
PrEP coverage and billing
Pre‑Exposure Prophylaxis (PrEP) coverage requirements, baseline testing, monitoring, coding and billing instructions.
PrEP and HIV screening coverage criteria
Coverage stance and frequency criteria for PrEP and HIV screening under Medicare and for Community Care/MassHealth members.
Preventive services coverage criteria
Coverage and criteria for Medicare preventive visits, well visits, screenings, and select Community Care member screenings.
Preventive services coverage guidance (applicability fragment)
Additional preventive services guidance, coding notes, place‑of‑service applicability, and references to other Plan policies.
Codes and Billing Identifiers
| 76706 | Ultrasound, abdominal aorta, screening study for abdominal aortic aneurysm (AAA) |
| 11976-11983, 57170, 58300-58301, 58565, 58615, 58670-58671 | Procedures related to contraceptive devices, IUD insertion/removal, tubal occlusion/ligation, and diaphragm/cervical cap fitting |
| A4261, A4266, J7296-J7301, J7303, J7307 | Contraceptive supplies and intrauterine systems and implants |
| 81212-81217 | BRCA1/BRCA2 gene analysis codes |
| 77067, 77063, 77046-77049, 76641-76642 | Screening mammography, tomosynthesis, breast MRI, and breast ultrasound codes |
| 88141-88175 | Cytopathology codes for cervical cancer screening |
| 87491, 87591 | NAAT codes for Chlamydia and Gonorrhea detection |
| 45330-45346, 45378-45392, 74261-74263, 81528, 0464U, 0537U, G0104, G0121, G0327, G0500 | Colorectal screening colonoscopy/sigmoidoscopy, CT colonography, multitarget stool DNA and blood-based biomarker test codes and related procedural codes |
| G0105 | Colorectal cancer screening; colonoscopy for high risk |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
| G0327 | Colorectal cancer screening; fecal occult blood test / FIT |
| G0500 | Moderate sedation services; initial 15 minutes |
| 99153 | Moderate sedation; each additional 15 minutes |
| G0444 | Annual depression screening, up to 15 minutes |
| 99188 | Application of topical fluoride varnish by physician or qualified health care professional |
| D1206 | Topical application of fluoride varnish (dentist) |
| 87340 | Hepatitis B surface antigen (HBsAg) |
| 86803 | Hepatitis C antibody |
| G0472 | Hepatitis C antibody screening for high risk |
| G0567 | Hepatitis C nucleic acid screening, amplified probe technique |
| 82565 | Creatinine; blood |
| 87491 | Chlamydia trachomatis, amplified probe |
| 87591 | Neisseria gonorrhoeae, amplified probe |
| 87801 | Combined chlamydia and gonorrhea amplified probe |
| 86592 | Syphilis non-treponemal qualitative |
| J0739 | Injection, cabotegravir, 1 mg, for HIV PrEP (HCPCS) |
| J0799 | Unclassified drug code — used for FDA-approved PrEP drug not otherwise classified |
| G0011 | Individual counseling for PrEP by physician or QHP |
| G0012 | Injection of PrEP drug for HIV prevention |
| G0013 | Individual counseling for PrEP by clinical staff |
| G0432 | HIV-1 and/or HIV-2 screening by EIA (Medicare) |
| G0433 | HIV-1 and/or HIV-2 screening by ELISA (Medicare) |
| G0435 | Rapid HIV antibody test (Medicare) |
| G0475 | HIV antigen/antibody combination assay (Medicare) |
| 71271 | CT thorax low dose for lung cancer screening |
| 99381-99387, 99391-99397 | Initial and periodic comprehensive preventive medicine evaluation and management codes across age ranges (new and established patients) |
Required Provider Actions, Billing Notes, and Prior Authorization
Modifier 25 disclosure, diagnosis position, and payment split
When billing a problem-focused E&M on the same day as a preventive service, apply modifier 25 to the problem-focused E&M and disclose to the member if billing will result in cost-sharing; preventive services must be submitted with a preventive diagnosis in the primary position to avoid cost-sharing. Preventive service reimbursed at 100% and the problem-focused service reimbursed at 50% when modifier 25 is applied (commercial plans); Medicare Advantage members may owe cost-sharing when modifier 25 is used. Regular review of modifier 25 use for coding accuracy will occur.
- Preventive ICD-10 codes must be placed in the primary diagnosis position; if not, cost-sharing may apply.
- Providers must disclose to members when a problem-focused E&M is billed and will result in cost-sharing.
- When modifier 25 is correctly applied, preventive service reimbursed at 100% and problem-focused E&M at 50% of contracted rate for commercial members; Medicare Advantage members may be responsible for copayment/deductible.
Always report preventive diagnosis in primary position
Submit preventive services with preventive diagnosis codes in the primary diagnosis position on the claim; if a non-preventive diagnosis is in the primary position the service may be subject to member cost-sharing.
- Each claim line should indicate the applicable diagnosis; preventive diagnosis must be primary for the service to be considered preventive.
- Failure to use a preventive primary diagnosis may trigger member cost-sharing.
Obtain prior authorization for BRCA testing and high‑tech radiology
Obtain prior authorization where required: BRCA genetic testing and high‑tech radiology (including screening breast MRI) require prior authorization before services are rendered.
- BRCA gene analysis codes (e.g., 81212–81217) are considered preventive only with prior authorization.
- Screening breast MRI and other high‑tech radiology require prior authorization (effective coverage updates noted).
Use modifiers -53 (professional) or -73/-74 (facility) for interrupted colonoscopy
When a covered colonoscopy is attempted but cannot be completed due to extenuating circumstances, submit the professional claim with modifier -53 to indicate the interrupted procedure; facility claims should use modifier -73 or -74 as appropriate.
- Plan will pay for interrupted colonoscopy if coverage conditions are met.
- Professional providers suffix the colonoscopy code with modifier -53; facility claims use -73 or -74 as appropriate.
When and how to bill annual depression screening (G0444)
Bill HCPCS G0444 (annual depression screening, up to 15 minutes) only when staff‑assisted depression care supports are in place and do not report G0444 with IPPE (G0438), initial AWV (G0402) or comprehensive preventive medicine CPTs; G0444 may be billed via telehealth with POS 02 or 10 effective Jan 1, 2025.
Fluoride varnish — exact CPT and ICD-10 pairing by program
For fluoride varnish, bill CPT 99188 with ICD-10 Z00.129 for EPSDT MassHealth well‑child visits on or after Aug 19, 2025; when billed for other visits use CPT 99188 with ICD-10 Z41.8. For Community Care members, bill CPT 99188 with ICD-10 Z29.3; dentists may bill D1206 only for members with preventive dental coverage.
Perform baseline labs and quarterly HIV testing while on PrEP
Before initiating PrEP, obtain baseline testing (HIV, HBV, HCV, pregnancy when applicable, creatinine with eCrCl/eGFR) and STI screening; while on PrEP perform HIV testing every three months and periodic STI screening and counseling as part of monitoring.
- Baseline labs required prior to PrEP initiation: HIV, HBV, HCV, pregnancy test if applicable, renal function (creatinine, eCrCl/eGFR).
- Repeat HIV testing every 3 months while taking PrEP; counseling and STI screening are integral components of PrEP care.
- Use recommended CPT/HCPCS lab and counseling codes per guidance (see PrEP coding lists).
Medicare NCD 210.15 — PrEP covered under Part B with no cost‑sharing
For Medicare members, PrEP drugs and associated clinical and laboratory services are covered under Medicare Part B per NCD 210.15 (effective 9/30/2024) with no deductibles, copayments, or coinsurance for individuals determined by a clinician to be at increased risk of HIV acquisition.
- NCD 210.15 directs Medicare to cover all forms of PrEP (oral and injectable) under Part B with no cost-sharing.
- Determination of 'increased risk' is made by a physician or health care practitioner.
- NCD includes coverage of up to eight counseling visits and up to eight HIV screening tests per 12 months and a single HBV screening with no cost-sharing.
Obtain prior authorization for LDCT (CPT 71271) when applicable
Prior authorization is required for LDCT lung cancer screening (CPT 71271) for commercial and MassHealth ACO members; note prior authorization exceptions for some Medicare plan types per updated guidance.
Pharmacists cannot be paid directly under Medicare Part B — use 'incident to' billing when applicable
Pharmacists are not eligible for direct payment under Medicare Part B; pharmacist‑provided PrEP services (counseling, injection, ordering) cannot be paid directly to pharmacists and must be billed 'incident to' a supervising physician/practitioner when all incident‑to conditions and supervision requirements are met.
- Pharmacist services may be provided 'incident to' and billed by the supervising physician/practitioner when regulatory supervision and incident‑to conditions are satisfied.
- Refer to 42 CFR §§ 410.26 and 410.27 for incident‑to regulations and CMS incident‑to guidance.
Offer postpartum depression screening and refer if positive (Community Care)
Offer and perform postpartum depression and major depressive disorder screening for Community Care postnatal individuals within 12 months of birth, adoption/foster custody, or pregnancy loss; if screening is positive, document discussion of treatment options and refer to a mental health clinician. Screening performed as part of a global obstetrical service is considered part of the global package and is not separately reimbursed.
- Postnatal individuals include birth, adoption/foster custody within 12 months, or recent pregnancy loss.
- Providers (PCP, OB/GYN, CNM, licensed midwife, pediatrician) must offer screening and ensure appropriate screening per evidence‑based guidelines.
- If screening positive, discuss treatments and provide referral; screenings in a global obstetrical service are not separately reimbursed.
Report separate E/M with modifier 25 when provided with IPPE/AWV
If a significant, separately identifiable E/M is provided during an IPPE or AWV, report the appropriate E/M CPT code (99202–99215) with modifier 25 to indicate the separate service.
Bill G0136 with modifier 33 for SDOH assessment when done with AWV
When providing an annual SDOH assessment on the same day as an AWV, provide the assessment on the same day by the same provider and bill HCPCS G0136 with modifier 33 on the same claim as the AWV.
- SDOH assessment must follow standardized evidence‑based practices and be culturally/linguistically appropriate.
- Bill G0136 with modifier 33 on the same claim as the AWV and ensure the same provider furnishes the AWV and the assessment.
Policy applies to services in all settings (place of service)
This policy applies to services rendered in all settings; all preventive coverage, billing and coding rules in this document apply regardless of place of service.
- Place of service applicability: policy covers services in all settings.
- Providers should follow the same billing/coding rules for preventive services in any setting.
Definitions and Term Guidance
Policy Revision History and Effective Dates
Policy origination recorded; initial policy history entry.
Updated discussion of preventive services with evaluation and management codes and migrated to Fallon Health template.
Annual review and moved to new plan template.
Added CPT codes 99497 and 99498 to preventive services coding.
Added coding to billing/coding section.
Annual review with no updates.
Updated billing/coding guidelines for colorectal cancer screening, pediatric hearing screening, Hepatitis C screening, and lung cancer screening.
Reflected that prior authorization is not required for LDCT lung cancer screening (CPT 71271) for Medicare members.
Added new lung cancer screening LDCT eligibility criteria for Medicare members.
Updated alcohol misuse screening guidance for Medicare, added asymptomatic bacteriuria screening, and revised developmental/behavioral screening and colorectal cancer screening sections.
Added CPT 84703, 84705 and 87535 to recommended CPT codes for PrEP billing and updated HIV screening section.
Updated screening mammography codes and added instructions for ICD-10-CM code Z29.81 for PrEP encounters.
Clarified MassHealth and Medicare coverage for alcohol screening codes and noted G0444 noncoverage for MassHealth ACO members under depression screening.
Removed select S-codes under preventive exams and added sections for Medicare Wellness Visits and NCD 210.1 (Pap/ pelvic screening).
Added Medicare PrEP section, updated MassHealth pediatric caregiver screening timing per Chapter 186 (Acts of 2024), and added Community Care postnatal depression screening guidance; allowed telehealth for annual depression screening.
Updated breast cancer screening, fluoride varnish services, Hepatitis C and colorectal screening per recent transmittals, and added MassHealth Perinatal Depression Screening guidance.
Policy effective date set to March 1, 2026.
This payment policy is effective 03/01/2026. It provides Fallon Community Health Plan's billing, coding, and reimbursement rules for preventive services across Fallon Health products and subsidiaries. The policy notes that specific provider contract terms and individual member benefit plans may affect payment and that the Plan may audit claims and reclaim overpayments.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.